Bruce C. Robertson - 03 Aug 2021 Form 4 Insider Report for RxSight, Inc. (RXST)

Reporting relationship: Director
Issuer ticker: RXST
Reported as of: 03 Aug 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Aug 2021, 19:48:33 UTC
Prior SEC filing: 29 Jul 2021
Source filing: View source filing
Reporting owner signature: /s/ Shelley Thunen, as Attorney-in-Fact

Key filing fact

Bruce C. Robertson filed Form 4 for RxSight, Inc. (RXST) on 05 Aug 2021.

Key facts

This page summarizes Bruce C. Robertson's Form 4 filing for RxSight, Inc. (RXST).
7 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 05 Aug 2021, 19:48.

Change

Previous filing in this sequence was filed on 29 Jul 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RXST transaction

Common Stock

Conversion of derivative security

Transaction value: $0
Shares: +1,385,037
Change %
Price: $0.000000
Shares after: 1,385,037
Date: 03 Aug 2021
Ownership: See footnote
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RXST transaction Derivative

Series G Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -968,054
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 03 Aug 2021
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 968,054
Exercise price
Footnotes: F1, F3

RXST transaction Derivative

Series H Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -403,355
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 03 Aug 2021
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 403,355
Exercise price
Footnotes: F2, F3

RXST transaction Derivative

Warrant (right to buy)

Options Exercise

Transaction value: $0
Shares: -60,503
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 03 Aug 2021
Ownership: See footnote
Underlying class: Series H Preferred Stock
Underlying amount: 60,503
Exercise price: $12.40
Footnotes: F2, F3, F4

RXST transaction Derivative

Series H Preferred Stock

Options Exercise

Transaction value: $0
Shares: +60,503
Change %
Price: $0.000000
Shares after: 60,503
Date: 03 Aug 2021
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 60,503
Exercise price
Footnotes: F2, F3, F4

RXST transaction Derivative

Series H Preferred Stock

Tax liability

Transaction value: $0
Shares: -46,875
Change %: -77%
Price: $0.000000
Shares after: 13,628
Date: 03 Aug 2021
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 46,875
Exercise price
Footnotes: F2, F3, F4

RXST transaction Derivative

Series H Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -13,628
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 03 Aug 2021
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 13,628
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Bruce C. Robertson is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

Footnote F2

Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein.

Footnote F3

All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

Footnote F4

The warrant was automatically net exercised for Series H Preferred Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.